Bibliography
- Lee SJ , ChinenJ, KavanaughA: Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins.J. Allergy Clin. Immunol.125(Suppl. 2), S314–S323 (2010).
- Chan AC , CarterPJ: Therapeutic antibodies for autoimmunity and inflammation.Nat. Rev. Immunol.10, 301–316(2010).
- Dinarello CA : Anti-inflammatory agents: present and future.Cell140, 935–950(2010).
- Ilowite NT : Update on biologics in juvenile idiopathic arthritis.Curr. Opin. Rheumatol.20(5), 613–618(2008).
- Beresford MW , BaildamEM: New advances in the management of juvenile idiopathic arthritis-2: the era of biological.Arch. Dis. Child Educ. Pract. Ed.94, 151–156(2009).
- Breda L , Del Torto M, De Sanctis S, Chiarelli F: Biologics in Children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. doi:10.1007/s00431–010–1238-z. (2010) (Epub ahead of print).
- Singh JA , ChristensenR, WellsGAet al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews.Cochrane Database Syst. Rev.4, 1–79(2009).
- Raychaudhuri SP , NguyenCT, RaychaudhuriSK, GershwinME: Incidence and nature of infectious disease in patients treated with anti-TNF agents.Autoimmun. Rev.9, 67–81(2009).
- Salvana EM , SalataRA: Infectious complications associated with monoclonal antibodies and related small molecules.Clin. Microbiol. Rev.22, 274–290(2009).
- Lovell DJ , ReiffA, IlowiteNTet al.; Pediatric Rheumatology Collaborative Study Group: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum.58(5), 1496–1504(2008).
- Giannini EH , IlowiteNT, LovellDJet al.; Pediatric Rheumatology Collaborative Study Group: Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum.60(9), 2794–2804(2009).
- Horneff G , SchmelingH, BiedermannTet al.: The German etanercept registry for treatment of juvenile idiopathic arthritis.Ann. Rheum. Dis.63(12), 1638–1644(2004).
- Horneff G , De Bock F, Foeldvari I et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group: Safety and efficacy of combination of etanercept and methotrexate compared with treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis.68(4), 519–525(2009).
- Dekker L , ArmbrustW, RademakerCM, PrakkenB, KuisW, WulffraatNM: Safety of anti-TNFα therapy in children with juvenile idiopathic arthritis.Clin. Exp. Rheumatol.22(2), 252–258(2004).
- Prince FHM , TwiltM, ten Cate R et al.: Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis.68, 635–641(2009).
- Pain CE , McCannLJ: Challenges in the management of juvenile idiopathic arthritis with etanercept.Biologics3, 127–139(2009).
- Burmester GR , MeaseP, DijkmansBAet al.: Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.Ann. Rheum. Dis.68(12), 1863–1869(2009).
- Ruperto N , LovellDJ, CutticaRet al.; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann. Rheum. Dis.69(4), 718–722(2010).
- Keane J , GershonS, WiseRPet al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent.N. Engl. J. Med.345(15), 1098–1104(2001).
- Frank KM , HogarthK, MillerJLet al.: Investigation of the cause of death in a gene-therapy trial.N. Engl. J. Med.361, 161–169(2009).
- Abinun M , FloodTJ, CantAJet al.: Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007).Mol. Immunol.47(1), 46–51(2009).
- Eleftheriou D , MeloM, MarksSDet al.: Biologic therapy in primary systemic vasculitis of the young.Rheumatology (Oxford).48(8), 978–986(2009).
- Maródi L , CasanovaJL: Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?Nat. Rev. Immunol.10(5), 299–300(2010).
- Puel A , PicardC, LorrotMet al.: Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6.J. Immunol.180(1), 647–654(2008).
- Yokota S , ImagawaT, MoriMet al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial.Lancet371(9617), 998–1006(2008).
- Cooper N , DaviesEG, ThrasherAJ: Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogglobulinaemia requiring replacement intravenous immunoglobulin.Br. J. Haematol.146(1), 120–122(2009)
- Terrier B , AmouraZ, RavaudPet al.; Club Rhumatismes et Inflammation: Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum. doi:10.1002/art.27541 (2010) (Epub ahead of print).
- Ruperto N , LovellDJ, QuartierPet al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum.62(6), 1792–1802(2010).
- Notarangelo LD , FischerA, GehaRSet al.; International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies: Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol.124, 1161–1178(2009).
- Casanova J -L, Abel L: Primary immunodeficiencies: a field in its infancy. Science317, 617–619(2007).
- Casanova J -L, Fieschi C, Zhang S-Y, Abel L: Revisiting human primary immunodeficiencies. J. Intern. Med.264, 115–127(2008).
- Patel SY , DoffingerR, Barcenas-MoralesG, KumararatneDS: Genetically determined susceptibility to mycobacterial infection.J. Clin. Pathol.61, 1006–1012(2008).
- Filipe-Santos O , BustamanteJ, ChapgierAet al.: Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features.Sem. Immunol.18, 347–361(2006).
- Bruns H , MeinkenC, SchauenbergPet al.: Anti-TNF immunotherapy reduces CD8+ T-cell mediated antimicrobial activity against Mycobacterium tuberculosis in humans.J. Clin. Investig.119, 1167–1177(2009).
- Miller EA , ErnstJD: Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.J. Clin. Investig.119, 1079–1078(2009).
- Harris J , KeaneJ: How tumour necrosis factor blockers interfere with tuberculosis immunity.Clin. Exp. Immunol.161, 1–9(2010).
- Medzhitov R : Recognition of microorganisms and activation of the immune response.Nature449(7164), 819–826(2007).
- Medzhitov R : Inflammation 2010: new adventures of an old flame.Cell140(6), 771–776(2010).
- Schroder K , TschoppJ: The inflammasomes.Cell140, 821–832(2010).
- Döffinger R , SmahiA, BessiaCet al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling.Nat. Genet.27(3), 277–285(2001).
- Picard C , PuelA, BonnetMet al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency.Science.299(5615), 2076–2079(2003).
- von Bernuth H , PicardC, JinZet al.: Pyogenic bacterial infections in humans with MyD88 deficiency.Science.321(5889), 691–696(2008).
- von Bernuth H , PuelA, KuCLet al.: Septicemia without sepsis: inherited disorders of nuclear factor-κ B-mediated inflammation.Clin. Infect. Dis.41(Suppl. 7), S436–S439 (2005).
- Masters SL , SimonA, AksentijevichI, KastnerDL: Horror autoinflammatoricus: The molecular pathophysiology of autoinflammatory disease.Annu. Rev. Immunol.27, 621–668(2009).
- Kastner DL , AksentijevichI, Goldbach-ManskyR: Autoinflammatory disease reloaded: a clinical perspective.Cell140, 784–790(2010).
- Henderson C , Gorbach-ManskyR: Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals.Clin. Immunol.135, 210–222(2010).
- Goldbach-Mansky R , DaileyN J, Canna SW et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1{β} inhibition. N. Engl. J. Med.355, 581–592(2006).
- Lachmann HJ , Kone-PautI, Kuemmerle-DeschnerJBet al.: (Canakinumab in CAPS Study Group). Use of canakinumab in the cryopyrin-associated periodic syndrome.N. Engl. J. Med.360(23), 2416–2425(2009).
- Pascual V , AllantazF, ArceE, PunaroM, BanchereauJ: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.J. Exp. Med.201, 1479–1486(2005).
- Gattorno M , PicciniA, Lasigli'eDet al.: The pattern of response to anti–interleuk in-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.Arthritis Rheum.58(5), 1505–1515(2008).
- Ohlsson V , BaildamE, FosterH, JandialS, PainC, StrikeH, RamanAV: Anakinra treatment for systemic onset juvenile idiopathic arthritis (soJIA).Rheumatology47, 555–556(2008).
- Dinarello CA : Blocking IL-1 in systemic inflammation.J. Exp. Med.201, 1355–1359(2005).
- Diak P , SiegelJ, La Grenade L, Choi L, Lemery S, McMahon A: Malignancy in children and tumor necrosis factor-α blockers: forty-eight cases reported to the food and drug administration. Arthritis Rheum. doi:10.1002/art.27511 (2010) (Epub ahead of print).
- McCroskery P , WallaceCA, LovellDJet al.: Summary of worldwide pediatric malignancies reported after exposure to etanercept.Pediatr. Rheumatol. Online J.8(1), 18 (2010).
- Smith MY , SobelRE, WallaceCA: Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry.Arthritis Care Res.62, 800–804(2010).
- Lepore L , PaloniG, CaorsiRet al.: Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra.J. Pediatr. doi:10.1016/j.jpeds.2010.02.040. (2010) (Epub ahead of print).
- Solovic I , SesterM, Gomez-ReinoJJet al.: The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement.Eur. Respir. J. doi: 09031936.00028510v1-erj00285–2010 (2010) (Epub ahead of print).
- Centers for Disease Control and Prevention: updated guidelines for using interferon γ release assays to detect Mycobacterium tuberculosis infection; United States, 2010. MMWR59(RR-5), 1–25(2010).
Websites
- FDA alert (9/4/2008): The US FDA information for healthcare professionals that histoplasmosis and other invasive fungal infections are not consistently recognized in patients taking TNF blockers, which has resulted in delays in appropriate treatment, sometimes resulting in death www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm
- FDA alert (4/8/2009): The US FDA warning, highlighting the increased risk of cancer in children and adolescents who receive TNF blockers www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm